Breast Cancer Research
Genetic and molecular signatures have been incorporated into cancer prognosis prediction and treatment decisions with good success over the past decade. Clinically, these signatures are usually used in early-stage cancers to evaluate whether they require adjuvant therapy following surgical resection. A molecular signature that is prognostic across more clinical contexts would be a useful addition to current signatures. We defined a signature for the ubiquitous tissue factor, E2F4, based on its shared target genes in multiple tissues. These target genes were identified by chromatin immunoprecipitation sequencing (ChIP-seq) experiments using a probabilistic method. We then computationally calculated the regulatory activity score (RAS) of E2F4 in cancer tissues, and examined how E2F4 RAS correlates with patient survival.
Khaleel, Sari S.; Andrews, Erik H.; Ung, Matthew; DiRenzo, James; and Chung, Chao, "E2F4 Regulatory Program Predicts Patient Survival Prognosis in Breast Cancer" (2014). Open Dartmouth: Faculty Open Access Articles. 1316.